Galenica Announces Completion of Relypsa (RLYP) Acquisition

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:31 AM EDT

Vifor Pharma Ltd. / Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®
  Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key... More

Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies

September 2, 2016 1:21 AM EDT

Combination with Relypsa strengthens Vifor Pharma's position as a leading speciality pharmaceutical company, bringing global rights to hyperkalaemia treatment Veltassa®   Vifor Pharma to build on Relypsa's fully-integrated commercial organisation in key US cardio-renal market by leveraging its extensive and growing specialty portfolio

GLATTBRUGG, Switzerland, Sept. 2, 2016 (GLOBE NEWSWIRE) -- Galenica Group today announced that it has completed its previously announced acquisition of Relypsa, Inc., (NASDAQ: RLYP). The combination of Galenica's Vifor Pharma business unit with Relypsa will create a significant player in cardio-renal care in the US and further strengthen Vifor Pharma's growing... More